Vistage

Vistagen is a clinical-stage biopharmaceutical company focused on developing innovative therapies for psychiatric and neurological disorders. The company's pipeline is centered on a new class of drugs called pherines, which are synthetic neuroactive steroids designed to be administered as nasal sprays. These compounds target chemosensory receptors in the nasal passages to achieve rapid-onset effects without systemic absorption or significant side effects. Their lead candidate, fasedienol (PH94B), is currently in Phase 3 development for the acute treatment of social anxiety disorder. Vistagen also has programs targeting major depressive disorder, postpartum depression, and other CNS-related conditions. The company aims to provide fast-acting, non-systemic treatment options that address the limitations of current standard-of-care medications.